Co-founder & CEO
Ryan Cirz, PhD, has spent over two decades focused on the discovery and development of novel antibacterials for high unmet medical needs.
At Achaogen, a San Francisco-based biotech which he helped found, he witnessed firsthand the evolution of both the pathogens being targeted and the regulatory framework to obtain market authorization for new, innovative products. While Achaogen grew from academic startup to a >$1B NASDAQ-valued public company, it struggled to find a commercial footing with its breakthrough-therapy-designated lead product. He spent the latter part of his time at Achaogen both overseeing the research pipeline and working closely with the commercial/field team, end-users, charities/NGOs, and government stakeholders to seek to understand the driving forces behind the commercial struggles.
He carried those learnings to Revagenix where he continues to focus on extreme unmet medical needs with a lens on solutions to the barriers to patient access and commercial success.
Dr. Cirz received his PhD from The Scripps Research Institute and BS from The Pennsylvania State University where he still serves as an industry advisor to the Eberly College of Science.
Ryan Cirz, PhD
Co-founder & CEO
Co-founder & COO
Andrew McCandlish, PhD, has 20 years of experience in pharmaceutical and medical device corporate development and operations. In his current role as Chief Operating Officer at Revagenix, Dr. McCandlish is accountable for all business areas outside of R&D, including finance/accounting, corporate development, legal, and alliance management. Previously as Head of US Business Development at pH Pharma, he was responsible for partnering for oncology, NASH, and rare disease programs, and as acting VP of Business Development at Meissa Vaccines he negotiated licenses for vaccine candidates and supported the company’s Series A financing. At Achaogen, Dr. McCandlish led research partnering efforts and supported commercial inlicensing, and secured or supported administration of approximately $350 million of non-dilutive funding. He also had operational responsibilities in developing and commercializing a therapeutic drug monitoring (TDM) assay for Zemdri (plazomicin).
Dr. McCandlish has led and supported efforts to fund multiple biotech and diagnostics companies through private investments from venture capital firms and angel investors, authoring S1/S3s for an IPO and follow-on financings.
Dr. McCandlish received his PhD in Molecular Biology from Princeton University, where he studied outer membrane biogenesis in Escherichia coli in the laboratory of Thomas J. Silhavy, and his BS with Honors from The Ohio State University in Molecular Genetics/Business Marketing (Capital Program).
Andrew McCandlish, PhD
Co-founder & COO
Chief Scientific Officer
Peter Smith leads Revagenix’s scientific strategy, guiding Rev-56 through clinical development and shaping the science behind the company’s purpose-built approach to serious chronic diseases.
Peter joined Revagenix in 2022 and has led the science of the Rev-56 program — from candidate selection through a rigorous preclinical program and into the clinic. He brings more than 15 years of drug discovery and development experience. Before Revagenix, he spent eight years at Genentech, where he led research teams advancing novel small molecule therapeutics programs — two of which reached Phase 1 — and earlier co-founded RQx Pharmaceuticals.
Peter received his PhD in chemical biology from The Scripps Research Institute, and his BS from Purdue University with majors in biology and biochemistry. He has co-authored 26 peer-reviewed publications, is a named inventor on eight granted patents, and has served as chair of the Gordon Research Conference on New Antibacterial Discovery and Development.
Peter Smith, PhD
Chief Scientific Officer
VP, Development
Daniel Cloutier, PharmD, has been dedicated to the research and development of infectious disease products for 14 years, including IND through registration-enabling studies leading to the approvals of 2 marketed Gram-negative antibiotics, Zerbaxa (ceftolozane/tazobactam) and Zemdri (plazomicin). He now leads the development functions at Revagenix and is accountable for overseeing studies enabling IND through registration for Revagenix product candidates.
Dr. Cloutier's industry career started as a clinical scientist at Cubist Pharmaceuticals, where he supported the late-stage development and market applications (NDA and MAA) for ceftolozane/tazobactam. Following successful approvals of ceftolozane/tazobactam by FDA and EMA, and the acquisition of Cubist by Merck, he joined Achaogen, where he took on roles of increasing responsibilities directing the late-stage development of plazomicin, a novel aminoglycoside, through FDA approval. Prior to joining Revagenix, Dr. Cloutier served as a Sr. Director of Clinical Research at Vir Biotechnology, where he was global clinical lead overseeing multiple programs focused on the functional cure of both hepatitis B as well as hepatitis D co-infection.
Dr. Cloutier received his PharmD from the Massachusetts College of Pharmacy and Health Sciences.
Daniel Cloutier, PharmD
VP, Development
Board Chair
Founder & Principal, Lindrow
Tina Marriott has served as Board Chair and member of the Revagenix board since 2021.
Ms. Marriott is the Founder and Principal of Lindrow, and former President & COO of Recursion, where she helped grow the company from Series B to a global, publicly traded leader in AI-driven drug discovery. She was previously Senior Vice President, Executive Committee member, and Compliance Committee member at Achaogen, a publicly traded biopharmaceutical company that discovered, developed and commercialized treatments for infectious disease from May 2016 to June 2018, where she led Achaogen’s technical operations team—accountable for process development, supply chain and diagnostic development. Prior to Achaogen, she was Global Head of Technical Development Business Operations at Roche from October 2014 to April 2016, where she was responsible for business and technology infrastructure.
She spent a total of 20 years at Genentech/Roche in technical operations roles that included Automation Engineer, Associate Director Manufacturing Sciences, Director Process Development Engineering and Senior Director Technical Development Operations & Engineering. She has both deep technical expertise in scale-up of biopharmaceutical production and managing technical and operational organizations.
Ms. Marriott was recognized by the Healthcare Business Women’s Association as a Rising Star in 2012, was recognized by Utah Business magazine as CXO of the Year in 2020, and was a 2019 Women Tech Council Awards winner. She served on the Utah System of Higher Education governing board from 2023-2025. In addition, Ms. Marriott has been a member of the advisory board of Colorado State University’s College of Engineering since 2015 and was recognized in 2019 as a CSU Distinguished Alumni. Ms. Marriott received a B.S. in Chemical Engineering from Colorado State University.
Tina Marriott
Board Chair
Founder & Principal, Lindrow
CEO, Mobius Care
Cristina Larkin has served as a member of the Revagenix board since 2023.
Ms. Larkin has over 25 years of experience in senior leadership roles in the biopharmaceutical industry. She currently serves as Chief Executive Officer of Mobius Care, a precision medicine company dedicated to transforming inflammatory bowel disease treatment. Prior to Mobius, she served as the Chief Operating Officer and a member of the executive team of Spero Therapeutics, a publicly traded biotech company. In this role, she played a key role in helping the company transition from a preclinical private company to a public company with three late-stage clinical assets.
Prior to joining Spero Therapeutics, Ms. Larkin worked as an Assistant Vice President at Allergan (formerly known as Actavis/Forest Labs) from 2004 to 2015. During her tenure, she held various senior leadership positions. From 1994 to 2004, she worked at Ortho-McNeil Pharmaceuticals, a J&J company, where she held various senior leadership roles in marketing, market access, sales, and sales management.
Currently, Ms. Larkin works as an advisor to various investment and biotech companies and is an EIR (Executive in Residence) for Cleveland Clinic Innovations Fund and Columbia Technology Ventures. She also serves as a member of the Board of Directors for APUA, Alliance for Prudent Use of Antibiotics, and Florida State College of Business, BAISSC. Ms. Larkin earned her B.S. from Florida State University.
Cristina Larkin
CEO, Mobius Care
Tenmile
Michael Lamprecht, PhD, has served as a member of the Revagenix board since 2023.
Dr. Lamprecht is an Investment Associate at Tenmile, based in Sydney, specializing in biotechnology, startups, and early-stage investments. With over 15 years in the field, he has a unique background in developing regulatory and clinical strategies for novel cell-based therapies. His previous roles include Entrepreneur-in-Residence at Xora Innovation, Singapore, and Director of Regulatory Affairs at EpiBone, a U.S. biotech firm pioneering adult stem cell-based bone and cartilage grafts. Dr. Lamprecht holds a PhD in biomedical engineering from Columbia University, along with a bachelor’s degree in biomedical engineering from Boston University.
Michael Lamprecht, PhD
Tenmile
Representative, Novo Holdings
Bruce Montgomery, MD, has served as a member of the Revagenix board since 2024. Prior to this, he was a board observer in 2021 and an advisor since 2020.
Most recently, Dr. Montgomery served as CEO of Avalyn Pharma and has more than 34 years of life science operations and financing experience. Prior to Avalyn, Dr. Montgomery served as Chief Executive Officer of Cardeas, Senior Vice President of Gilead Sciences, and founder and Chief Executive Officer of Corus Pharma (acquired by Gilead in 2006). Dr. Montgomery has raised over 250 million dollars in venture and public financings, has over 20 years of public company board service, and is currently on the board of Xencor.
In 1998, Dr. Montgomery was recognized by the FDA Commissioner with a special citation for leadership in the development and approval of TOBI. For this work, Dr. Montgomery also received the Inventor of the Year award from the University of Washington and received a scientific achievement award from the Cystic Fibrosis Foundation for his work on medications which collectively have extended the average life span of cystic fibrosis patients by over a decade.
Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major [Merck Award]), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. In 2012, Dr. Montgomery was honored as one of the top 150 living graduates of the University of Washington College of Arts and Sciences in conjunction with the 150th anniversary of the university. Dr. Montgomery is a board certified internist and pulmonologist.
Bruce Montgomery, MD
Representative, Novo Holdings
J. Kevin Judice, PhD, has served as a member of the Revagenix board since 2025.
Dr. Judice most recently served as Senior Vice President, Lilly Research Laboratories while continuing as CEO of DICE Therapeutics following its acquisition by Eli Lilly and Company in 2023. Prior to founding DICE, Dr. Judice served as Chief Scientific Officer at Cidara Therapeutics, an antifungal company he helped found in 2012. In 2004, Dr. Judice co-founded Achaogen, Inc. (Nasdaq: AKAO), where, as the first employee, he was the Chief Scientific Officer and Chief Executive Officer. During his seven-year tenure at Achaogen, he oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, Dr. Judice served as the Vice President of Chemistry at Theravance, where he led the discovery of Vibativ (televancin).
Dr. Judice received his PhD in organic chemistry from the University of California Los Angeles and did his postdoctoral fellowship at the University of California Berkeley. He received his Bachelor of Science in chemistry from Texas A&M University. Dr. Judice is also a Henry Crown Fellow at the Aspen Institute.
J. Kevin Judice, PhD
Co-founder & CEO
Ryan Cirz, PhD, has spent over two decades focused on the discovery and development of novel antibacterials for high unmet medical needs.
At Achaogen, a San Francisco-based biotech which he helped found, he witnessed firsthand the evolution of both the pathogens being targeted and the regulatory framework to obtain market authorization for new, innovative products. While Achaogen grew from academic startup to a >$1B NASDAQ-valued public company, it struggled to find a commercial footing with its breakthrough-therapy-designated lead product. He spent the latter part of his time at Achaogen both overseeing the research pipeline and working closely with the commercial/field team, end-users, charities/NGOs, and government stakeholders to seek to understand the driving forces behind the commercial struggles.
He carried those learnings to Revagenix where he continues to focus on extreme unmet medical needs with a lens on solutions to the barriers to patient access and commercial success.
Dr. Cirz received his PhD from The Scripps Research Institute and BS from The Pennsylvania State University where he still serves as an industry advisor to the Eberly College of Science.
Ryan Cirz, PhD
Co-founder & CEO
Tenmile is a dedicated health technology investment business owned by Tattarang, one of Australia’s largest private investment groups. With an initial capital allocation of $250 million, we act fast and with confidence, investing without some of the constraints of other venture capital funds. Focused on supporting and building early-stage companies, we have the know-how, networks, and evergreen capital to partner through all stages of growth. With team members in Perth, Sydney, and San Francisco, we seek to address unmet needs in human health and support the development of a globally significant health science and technology sector in Australia.
Tenmile
Headquartered in Copenhagen, with affiliates in San Francisco, Boston, London and Singapore, Novo Holdings is a world-leading life science investor with a focus on creating long-term value. The purpose of the investments of Novo Holdings is both to grow the assets of the Foundation and to deliver a return that the Foundation can distribute for scientific, social and humanitarian purposes to improve the lives of people and the sustainability of society.
Novo Holdings invested in Revagenix through the REPAIR Impact Fund, which it established to replenish the anti-infective pipeline and to combat antimicrobial resistance. The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund invests in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.
Novo Holdings
Revagenix is performing under contracts with NIAID for the development of therapeutic products for antibiotic resistant bacteria. We are proud to work with NIAID on the advancement of our programs. The expertise and resources brought to the table by this important partner enable the rapid advancement of our programs towards the clinic.
NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.
National Institute of Allergy and Infectious Diseases (NIAID)
